Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ENDRA Life Sciences Inc. is a U.S.-based medical technology company focused on developing advanced diagnostic imaging solutions aimed at improving the detection and management of chronic diseases. The company operates primarily in the medical imaging and diagnostics industry, with a specific emphasis on non-invasive technologies for assessing liver disease. Its core technology platform, TAEUS® (Thermo-Acoustic Enhanced Ultrasound), is designed to enhance conventional ultrasound by adding functional tissue composition data, addressing limitations of standard imaging methods.
The company’s primary product candidate, TAEUS® Liver, is being developed to identify and monitor fatty liver disease, including metabolic dysfunction–associated steatotic liver disease (MASLD). ENDRA is a development-stage company and has not yet commercialized products generating material revenue. Founded in 2007, the company has evolved from early-stage acoustic research into a focused effort to bring a clinically viable, point-of-care liver diagnostics platform through regulatory pathways, positioning itself as a potential lower-cost alternative to MRI-based diagnostics.
Business Operations
ENDRA conducts its business through a single operating segment focused on the research, development, and regulatory advancement of its TAEUS® imaging platform. Operations are conducted primarily through its wholly owned subsidiary, ENDRA Medical LLC, which holds the company’s intellectual property and manages day-to-day research and development activities. Revenue to date has been primarily derived from grants and limited collaboration-related activity rather than commercial sales.
The company’s operations include preclinical research, clinical feasibility studies, engineering development, and regulatory engagement with the U.S. Food and Drug Administration. ENDRA does not manufacture imaging systems at scale and relies on external vendors and contract manufacturers for prototyping and limited production. The company has explored strategic collaborations with established ultrasound system manufacturers; however, data inconclusive based on available public sources regarding any currently active commercial partnerships.
Strategic Position & Investments
ENDRA’s strategic focus is centered on advancing TAEUS® Liver toward regulatory clearance in the United States, supported by clinical validation studies intended to demonstrate equivalence or advantages versus MRI-based proton density fat fraction (PDFF) measurements. The company has publicly emphasized a strategy of targeting large, underserved patient populations where existing diagnostic tools are costly, inaccessible, or unsuitable for routine screening.
The company has not completed any transformative acquisitions and does not maintain a diversified investment portfolio. Instead, capital allocation has been directed toward internal research and development, intellectual property protection, and regulatory activities. ENDRA has highlighted interest in expanding the TAEUS platform to additional indications beyond liver disease; however, data inconclusive based on available public sources regarding timelines or funded development programs for such extensions.
Geographic Footprint
ENDRA Life Sciences is headquartered in Ann Arbor, Michigan, which serves as its primary center for corporate management and research activities. The company’s operations are predominantly based in North America, with clinical and research collaborations conducted primarily in the United States.
While ENDRA has engaged with international clinical investigators and maintains intellectual property protections in multiple jurisdictions, it does not currently operate dedicated offices or manufacturing facilities outside the United States. Its global footprint is therefore limited, with international presence largely tied to research, regulatory strategy, and future market planning rather than established commercial operations.
Leadership & Governance
ENDRA is led by an executive team with experience in medical imaging, healthcare technology, and public company management. The leadership team emphasizes disciplined capital allocation, regulatory execution, and strategic positioning within the diagnostic imaging ecosystem, particularly as it relates to cost-effective, point-of-care solutions.
Key executives include:
- Francois Michel – Chief Executive Officer
- L. Scott Little – Chief Financial Officer
The company is governed by a board of directors responsible for oversight of strategy, risk management, and regulatory compliance. ENDRA operates as a publicly traded company subject to U.S. securities regulations and reporting requirements, with governance practices aligned to standards applicable to Nasdaq-listed life sciences companies.